Magenta Therapeutics Inc (MGTA):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Magenta Therapeutics Inc (MGTA) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C8213
◆発行会社(調査会社):GlobalData
◆発行日:2018年10月
◆ページ数:44
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Magenta Therapeutics Inc (Magenta Therapeutics) formerly HSCTCo Therapeutics Inc, is a clinical-stage biotechnology company focused on developing novel medicines which revolutionizes bone marrow transplant for treating autoimmune diseases, blood cancers and rare genetic diseases. Its product candidates include C100, C200, and C300 which are targeted antibody-drug conjugates used for transplant conditioning methods to reduce hematopoietic stem cells (HSCs) and immune cells in bone marrow; MGTA-M100, for mobilization of hematopoietic stem cells (HSCs); MGTA-456, an allogeneic stem cell therapy that allows expansion of cord blood stem cells; and G100, targeting graft-versus-host disease (GvHD) causing donor T-cells. The company is funded by Third Rock Ventures LLC, and Atlas Venture Inc. Magenta Therapeutics is headquartered in Cambridge, Massachusetts, the US.

Magenta Therapeutics Inc (MGTA) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Magenta Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Magenta Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Magenta Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Magenta Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Magenta Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Magenta Therapeutics Inc, Pharmaceuticals & Healthcare, Deal Details 12
Venture Financing 12
Magenta Therapeutics Raises USD52 Million in Series C Financing 12
Magenta Therapeutics Raises USD50 Million in Series B Financing 14
Magenta Therapeutics Raises USD48.5 Million in Series A Venture Financing 16
Partnerships 17
Magenta Therapeutics Enters into Multi-Target Research Agreement with Heidelberg Pharma 17
Magenta Therapeutics Enters into Development and Manufacturing Agreement with Bachem Americas 18
Magenta Therapeutics Enters into Agreement with University of Minnesota 19
Magenta Therapeutics Enters into Partnership with Be The Match BioTherapies 20
Licensing Agreements 21
Magenta Therapeutics Enters into Licensing Agreement with Novartis for MGTA-456 21
Magenta Therapeutics Enters into a Licensing Agreement with Trianni 22
Magenta Therapeutics Enters into Licensing Agreement with President and Fellows of Harvard College 23
Equity Offering 24
Magenta Therapeutics Raises USD100 Million in IPO of Shares 24
Debt Offering 26
Magenta Therapeutics Raises USD6.5 Million in Private Placement of 6% Convertible Promissory Notes 26
Magenta Therapeutics Raises USD0.5 Million in Private Placement of Convertible Promissory Notes 27
Magenta Therapeutics Inc – Key Competitors 28
Magenta Therapeutics Inc – Key Employees 29
Magenta Therapeutics Inc – Locations And Subsidiaries 30
Head Office 30
Recent Developments 31
Financial Announcements 31
Aug 09, 2018: Magenta Therapeutics reports recent operational progress and second quarter 2018 financial results 31
Corporate Communications 32
Apr 09, 2018: Magenta Therapeutics Appoints Amy Ronneberg to its Board of Directors 32
Apr 06, 2018: Magenta Therapeutics Appoints Amy Ronneberg, President of Be The Match BioTherapies, to Board of Directors 33
Apr 03, 2018: Magenta Therapeutics announces departure of chief operating officer Bastiano Sanna, Ph.D. 34
Feb 21, 2018: Magenta Therapeutics Hires John Davis, MD, MPH, as Chief Medical Officer 35
Oct 24, 2017: Magenta Therapeutics Appoints Alison Lawton, Jeff Albers and Blake Byers to its Board of Directors 36
Legal and Regulatory 37
Sep 24, 2018: Magenta Therapeutics added to Russell 2000 and 3000 Indexes 37
Product News 38
12/11/2017: Magenta’s Expanded Stem Cell Product, MGTA-456, Engrafts in 100% of Patients, Leading to Robust Neutrophil and Immune Recovery in Two Phase II Clinical Studies 38
Dec 09, 2017: Magenta Therapeutics’ lead targeted antibody drug conjugate shows promising preclinical results for non-genotoxic conditioning for bone marrow transplant 39
05/10/2017: Magenta Therapeutics Announces New Clinical Data on its Lead Expansion Clinical Program, MGTA-456, Presented at American Society of Gene and Cell Therapy Annual Meeting 40
Clinical Trials 41
Apr 05, 2018: Magenta Therapeutics Announces First Patient Transplanted with MGTA-456 in Phase 2 Study in Inherited Metabolic Disorders 41
Nov 01, 2017: Magenta Therapeutics to Present Clinical Results and Preclinical Research at American Society of Hematology (ASH) Annual Meeting 42
Appendix 44
Methodology 44
About GlobalData 44
Contact Us 44
Disclaimer 44

List of Tables
Magenta Therapeutics Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Magenta Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Magenta Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Magenta Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Magenta Therapeutics Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Magenta Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Magenta Therapeutics Raises USD52 Million in Series C Financing 12
Magenta Therapeutics Raises USD50 Million in Series B Financing 14
Magenta Therapeutics Raises USD48.5 Million in Series A Venture Financing 16
Magenta Therapeutics Enters into Multi-Target Research Agreement with Heidelberg Pharma 17
Magenta Therapeutics Enters into Development and Manufacturing Agreement with Bachem Americas 18
Magenta Therapeutics Enters into Agreement with University of Minnesota 19
Magenta Therapeutics Enters into Partnership with Be The Match BioTherapies 20
Magenta Therapeutics Enters into Licensing Agreement with Novartis for MGTA-456 21
Magenta Therapeutics Enters into a Licensing Agreement with Trianni 22
Magenta Therapeutics Enters into Licensing Agreement with President and Fellows of Harvard College 23
Magenta Therapeutics Raises USD100 Million in IPO of Shares 24
Magenta Therapeutics Raises USD6.5 Million in Private Placement of 6% Convertible Promissory Notes 26
Magenta Therapeutics Raises USD0.5 Million in Private Placement of Convertible Promissory Notes 27
Magenta Therapeutics Inc, Key Competitors 28
Magenta Therapeutics Inc, Key Employees 29

List of Figures
Magenta Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Magenta Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Magenta Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Magenta Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Magenta Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Magenta Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Magenta Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Magenta Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

★海外企業調査レポート[Magenta Therapeutics Inc (MGTA):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Saudi Electricity Co:発電所・企業SWOT分析
    Saudi Electricity Co - Power Plants and SWOT Analysis, 2017 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, information on key employee …
  • Trusted Media Brands Inc:企業の戦略的SWOT分析
    Trusted Media Brands Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products a …
  • Vedanta Resources Plc:企業のM&A・事業提携・投資動向
    Vedanta Resources Plc - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Vedanta Resources Plc Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M …
  • Combined Motor Holdings Ltd.:戦略・SWOT・企業財務分析
    Combined Motor Holdings Ltd. - Strategy, SWOT and Corporate Finance Report Summary Combined Motor Holdings Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and s …
  • Syngene International Ltd (SYNGENE):企業の財務・戦略的SWOT分析
    Summary Syngene International Ltd (Syngene), a subsidiary of Biocon Ltd, is a clinical research and contract research and manufacturing organization. The organization offers research, development and manufacturing programs. It also provides discovery medicinal chemistry, small molecule development, …
  • BlackBerry Ltd:企業のM&A・事業提携・投資動向
    BlackBerry Ltd - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's BlackBerry Ltd Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestmen …
  • Glow Energy Public Co Ltd (GLOW)-エネルギー分野:企業M&A・提携分析
    Summary Glow Energy Public Company Limited (Glow Energy), a subsidiary of Engie S.A., is an energy utility company. It generates and supplies electricity to Electricity Generating Authority of Thailand (EGAT). The company also generates and supplies electricity, steam, processed water and chilled wa …
  • Lantronix, Inc. (LTRX):企業の財務・戦略的SWOT分析
    Lantronix, Inc. (LTRX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses an …
  • Central European Media Enterprises Ltd.:企業のM&A・事業提携・投資動向
    Central European Media Enterprises Ltd. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Central European Media Enterprises Ltd. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed re …
  • Intrusion Inc (INTZ):企業の財務・戦略的SWOT分析
    Summary Intrusion Inc (Intrusion) is a technology company. The company offers network monitoring and analysis solutions. Its product portfolio includes Savant, TraceCop that enables identification of malicious and illegal activities, Secure Tap a suite of network tap products that enables deployment …
  • Tanzania Electric Supply Co Ltd:発電所・企業SWOT分析
    Tanzania Electric Supply Co Ltd - Power Plants and SWOT Analysis, 2017 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, information on k …
  • Willis Lease Finance Corp (WLFC)
    Willis Lease Finance Corp (WLFC) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company
  • Green Dot Corporation:企業の戦略・SWOT・財務分析
    Green Dot Corporation - Strategy, SWOT and Corporate Finance Report Summary Green Dot Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Maistra d.d.:企業の戦略・SWOT・財務情報
    Maistra d.d. - Strategy, SWOT and Corporate Finance Report Summary Maistra d.d. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate a …
  • H&R GmbH & Co KGaA (2HR):企業の財務・戦略的SWOT分析
    H&R GmbH & Co KGaA (2HR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Cytox Ltd-医療機器分野:企業M&A・提携分析
    Summary Cytox Ltd (Cytox) is a diagnostic and prognostic service provider that develops services for neurodegenerative disorders. The company’s blood tests are used to predict, which patients with MCI will develop Alzheimer's disease. Its biomarkers are based on the cell cycle hypothesis of Alzheime …
  • APR Applied Pharma Research SA-製薬・医療分野:企業M&A・提携分析
    Summary APR Applied Pharma Research SA (APR) is a healthcare company which focuses on the development and licenses of healthcare products for rare therapeutic areas. The company offers consumer health products, prescription healthcare products and therapeutic products. APR’s product pipeline portfol …
  • Innate Immunotherapeutics Ltd (IIL):製薬・医療:M&Aディール及び事業提携情報
    Summary Innate Immunotherapeutics Ltd (Innate Immunotherapeutics), formerly Innate Therapeutics Ltd is a pharmaceutical company that develops therapeutic drugs for the treatment of cancer and infectious diseases. The company utilizes immunomodulator microparticle technology. It develops lead drug ca …
  • Cabot Oil & Gas Corp (COG):企業の財務・戦略的SWOT分析
    Cabot Oil & Gas Corp (COG) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesse …
  • Electricity Generating Authority of Thailand:企業の戦略・SWOT・財務情報
    Electricity Generating Authority of Thailand - Strategy, SWOT and Corporate Finance Report Summary Electricity Generating Authority of Thailand - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operati …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆